Oric Pharmaceuticals, Inc. SEC filings ORIC

Oric Pharmaceuticals, Inc. has 423 filings in SEC EDGAR's recent list, going back to Dec 13, 2019. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 3, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 23, 2026 (regulation fd disclosure, other events). The company's fiscal year ends on December 31.

Oric Pharmaceuticals, Inc. SEC filings
Form Description Filed Period
8-K Current report
Regulation FD disclosure, Other events
Oct 23, 2026 Oct 23, 2026
10-Q Quarterly report Aug 3, 2026 Jun 30, 2026
8-K Current report
Results of operations
Aug 3, 2026 Aug 3, 2026
S-8 Employee stock plan registration Jul 30, 2026 —
8-K Current report
Officer or director change
Jul 30, 2026 Jul 28, 2026
8-K Current report
Officer or director change, Shareholder vote results
Jun 22, 2026 Jun 18, 2026
10-Q Quarterly report May 4, 2026 Mar 31, 2026
8-K Current report
Results of operations
May 4, 2026 May 4, 2026
ARS Annual report to shareholders Apr 28, 2026 Dec 31, 2025
DEFA14A Additional proxy material Apr 28, 2026 —
DEF 14A Proxy statement Apr 28, 2026 Jun 18, 2026
8-K Current report
Other events
Mar 31, 2026 Mar 31, 2026
8-K Current report
Other events
Feb 23, 2026 Feb 23, 2026
424B5 Prospectus supplement Feb 23, 2026 —
S-8 Employee stock plan registration Feb 23, 2026 —
10-K Annual report Feb 23, 2026 Dec 31, 2025
8-K Current report
Results of operations
Feb 23, 2026 Feb 23, 2026
8-K Current report
Other events
Dec 8, 2025 Dec 6, 2025
8-K Current report
Regulation FD disclosure
Nov 13, 2025 Nov 13, 2025
10-Q Quarterly report Nov 13, 2025 Sep 30, 2025
8-K Current report
Results of operations
Nov 13, 2025 Nov 13, 2025
10-Q Quarterly report Aug 12, 2025 Jun 30, 2025
8-K Current report
Results of operations, Exit or restructuring costs
Aug 12, 2025 Aug 12, 2025
424B3 Prospectus Jun 24, 2025 —
EFFECT Filing Jun 20, 2025 —
CORRESP Letter to the SEC Jun 17, 2025 —
UPLOAD Letter from the SEC Jun 16, 2025 —
8-K Current report
Shareholder vote results
Jun 13, 2025 Jun 11, 2025
S-3 Shelf registration Jun 11, 2025 —
D Filing Jun 6, 2025 —
8-K Current report
Material agreement, Unregistered share sale, Regulation FD disclosure, Other events
May 28, 2025 May 23, 2025
10-Q Quarterly report May 5, 2025 Mar 31, 2025
8-K Current report
Results of operations
May 5, 2025 May 5, 2025
ARS Annual report to shareholders Apr 23, 2025 Dec 31, 2024
DEFA14A Additional proxy material Apr 23, 2025 —
DEF 14A Proxy statement Apr 23, 2025 Jun 11, 2025
S-8 Employee stock plan registration Mar 20, 2025 —
8-K Current report
Officer or director change
Mar 14, 2025 Mar 11, 2025
8-K Current report
Other events
Feb 25, 2025 Feb 25, 2025
10-K Annual report Feb 18, 2025 Dec 31, 2024
8-K Current report
Results of operations
Feb 18, 2025 Feb 18, 2025
8-K Current report
Regulation FD disclosure
Jan 13, 2025 Jan 13, 2025
10-Q Quarterly report Nov 12, 2024 Sep 30, 2024
8-K Current report
Results of operations
Nov 12, 2024 Nov 12, 2024
10-Q Quarterly report Aug 12, 2024 Jun 30, 2024
8-K Current report
Results of operations
Aug 12, 2024 Aug 12, 2024
8-K Current report
Shareholder vote results
Jun 14, 2024 Jun 12, 2024
10-Q Quarterly report May 6, 2024 Mar 31, 2024
8-K Current report
Results of operations
May 6, 2024 May 6, 2024
ARS Annual report to shareholders Apr 24, 2024 Dec 31, 2023
DEFA14A Additional proxy material Apr 24, 2024 —
DEF 14A Proxy statement Apr 24, 2024 Jun 12, 2024
S-8 Employee stock plan registration Mar 29, 2024 —
8-K Current report
Officer or director change
Mar 29, 2024 Mar 26, 2024
S-3ASR Automatic shelf registration Mar 11, 2024 —
10-K Annual report Mar 11, 2024 Dec 31, 2023
8-K Current report
Results of operations
Mar 11, 2024 Mar 11, 2024
EFFECT Filing Feb 2, 2024 —
CORRESP Letter to the SEC Jan 31, 2024 —
UPLOAD Letter from the SEC Jan 31, 2024 —
D Filing Jan 30, 2024 —
S-3 Shelf registration Jan 26, 2024 —
8-K Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
Jan 22, 2024 Jan 20, 2024
8-K Current report
Results of operations, Regulation FD disclosure
Jan 9, 2024 Jan 9, 2024
EFFECT Filing Dec 28, 2023 —
CORRESP Letter to the SEC Dec 26, 2023 —
UPLOAD Letter from the SEC Dec 22, 2023 —
S-3 Shelf registration Dec 15, 2023 —
8-K Current report
Other events
Dec 11, 2023 Dec 11, 2023
10-Q Quarterly report Nov 6, 2023 Sep 30, 2023
8-K Current report
Results of operations
Nov 6, 2023 Nov 6, 2023
8-K Current report
Other events
Oct 23, 2023 Oct 21, 2023
10-Q Quarterly report Aug 10, 2023 Jun 30, 2023
8-K Current report
Results of operations
Aug 10, 2023 Aug 10, 2023
D Filing Jul 5, 2023 —
8-K Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
Jun 27, 2023 Jun 24, 2023
8-K Current report
Shareholder vote results
Jun 15, 2023 Jun 14, 2023
10-Q Quarterly report May 8, 2023 Mar 31, 2023
8-K Current report
Results of operations
May 8, 2023 May 8, 2023
ARS Annual report to shareholders Apr 26, 2023 Dec 31, 2022
DEFA14A Additional proxy material Apr 26, 2023 —
DEF 14A Proxy statement Apr 26, 2023 Jun 14, 2023
8-K Current report
Bylaw or fiscal year change
Mar 24, 2023 Mar 20, 2023
S-8 Employee stock plan registration Mar 16, 2023 —
10-K Annual report Mar 16, 2023 Dec 31, 2022
8-K Current report
Results of operations
Mar 16, 2023 Mar 16, 2023
8-K Current report
Results of operations, Regulation FD disclosure
Jan 9, 2023 Jan 9, 2023
8-K Current report
Other events
Dec 21, 2022 Dec 21, 2022
424B5 Prospectus supplement Dec 21, 2022 —
10-Q Quarterly report Nov 7, 2022 Sep 30, 2022
8-K Current report
Results of operations
Nov 7, 2022 Nov 7, 2022
10-Q Quarterly report Aug 11, 2022 Jun 30, 2022
8-K Current report
Results of operations
Aug 11, 2022 Aug 11, 2022
SC TO-I/A Filing Jul 21, 2022 —
SC TO-I Filing Jun 21, 2022 —
8-K Current report
Shareholder vote results
Jun 21, 2022 Jun 17, 2022
10-Q Quarterly report May 9, 2022 Mar 31, 2022
8-K Current report
Results of operations
May 9, 2022 May 9, 2022
EFFECT Filing Apr 27, 2022 —
DEFA14A Additional proxy material Apr 27, 2022 —
DEF 14A Proxy statement Apr 27, 2022 Jun 17, 2022
S-8 Employee stock plan registration Mar 22, 2022 —
POS AM Filing Mar 22, 2022 —
8-K Current report
Regulation FD disclosure
Mar 21, 2022 Mar 21, 2022
10-K Annual report Mar 21, 2022 Dec 31, 2021
8-K Current report
Results of operations
Mar 21, 2022 Mar 21, 2022
POSASR Filing Mar 21, 2022 —
8-K Current report
Officer or director change
Mar 4, 2022 Mar 1, 2022
8-K Current report
Results of operations, Other events
Jan 10, 2022 Jan 10, 2022
8-K Current report
Officer or director change
Nov 10, 2021 Nov 9, 2021
10-Q Quarterly report Nov 8, 2021 Sep 30, 2021
8-K Current report
Results of operations
Nov 8, 2021 Nov 8, 2021
8-K Current report
Other events
Oct 7, 2021 Oct 7, 2021
8-K Current report
Other events
Aug 18, 2021 Aug 17, 2021
8-K Current report
Material agreement, Officer or director change
Aug 16, 2021 Aug 12, 2021
10-Q Quarterly report Aug 10, 2021 Jun 30, 2021
8-K Current report
Results of operations
Aug 10, 2021 Aug 10, 2021
8-K Current report
Other events
Jul 12, 2021 Jul 8, 2021
8-K Current report
Other events
Jul 8, 2021 Jun 28, 2021
8-K Current report
Shareholder vote results, Other events
Jun 21, 2021 Jun 16, 2021
8-K Current report
Material agreement
May 6, 2021 May 6, 2021
424B5 Prospectus supplement May 6, 2021 —
S-3ASR Automatic shelf registration May 6, 2021 —
10-Q Quarterly report May 6, 2021 Mar 31, 2021
8-K Current report
Results of operations
May 6, 2021 May 6, 2021
DEFA14A Additional proxy material Apr 26, 2021 —
DEF 14A Proxy statement Apr 26, 2021 Jun 16, 2021
S-8 Employee stock plan registration Mar 23, 2021 —
10-K Annual report Mar 23, 2021 Dec 31, 2020
8-K Current report
Results of operations
Mar 23, 2021 Mar 23, 2021
8-K Current report
Results of operations, Regulation FD disclosure
Jan 11, 2021 Jan 11, 2021
424B4 Prospectus Nov 13, 2020 —
S-1MEF Filing Nov 12, 2020 —
EFFECT Filing Nov 12, 2020 —
CORRESP Letter to the SEC Nov 10, 2020 —
CORRESP Letter to the SEC Nov 10, 2020 —
S-1 Registration statement Nov 10, 2020 —
10-Q Quarterly report Nov 5, 2020 Sep 30, 2020
8-K Current report
Results of operations
Nov 5, 2020 Nov 5, 2020
8-K Current report
Other events
Oct 19, 2020 Oct 19, 2020
10-Q Quarterly report Aug 5, 2020 Jun 30, 2020
8-K Current report
Results of operations, Unregistered share sale, Regulation FD disclosure
Aug 5, 2020 Aug 3, 2020
UPLOAD Letter from the SEC Jul 28, 2020 —
DRS Filing Jul 20, 2020 —
8-K Current report
Officer or director change
Jun 10, 2020 Jun 9, 2020
10-Q Quarterly report May 20, 2020 Mar 31, 2020
8-K Current report
Results of operations
May 20, 2020 May 20, 2020
8-K Current report
Bylaw or fiscal year change, Regulation FD disclosure
Apr 28, 2020 Apr 28, 2020
S-8 Employee stock plan registration Apr 24, 2020 —
424B4 Prospectus Apr 24, 2020 —
EFFECT Filing Apr 23, 2020 —
S-1MEF Filing Apr 23, 2020 —
CERT Filing Apr 23, 2020 —
CORRESP Letter to the SEC Apr 23, 2020 —
S-1/A Amended registration statement Apr 23, 2020 —
UPLOAD Letter from the SEC Apr 22, 2020 —
CORRESP Letter to the SEC Apr 21, 2020 —
CORRESP Letter to the SEC Apr 21, 2020 —
8-A12B Filing Apr 20, 2020 —
CORRESP Letter to the SEC Apr 20, 2020 —
S-1/A Amended registration statement Apr 20, 2020 —
UPLOAD Letter from the SEC Mar 9, 2020 —
CORRESP Letter to the SEC Mar 3, 2020 —
CORRESP Letter to the SEC Feb 28, 2020 —
S-1 Registration statement Feb 28, 2020 —
UPLOAD Letter from the SEC Feb 3, 2020 —
DRSLTR Filing Jan 24, 2020 —
DRS/A Filing Jan 24, 2020 —
UPLOAD Letter from the SEC Jan 9, 2020 —
DRS Filing Dec 13, 2019 —

Showing 170 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
ORIC (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
South San Francisco, CA
SEC filer status
Non-accelerated filer
SEC CIK
1796280

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.